Related Experiment Video
Updated: Apr 24, 2026
04:36
Author Spotlight: Time and Cost-Effective Fibrinogen-PAGE for Fibrinogenolytic Studies
Published on: April 19, 2024
960
Transient hypofibrinogenemia due to allopurinol
ZhiQiang Yin1, JiaLi Xu2, YongQiang Li3
1Department of Dermatology The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Drug Design, Development and Therapy
|September 13, 2014
Summary
An 80-year-old male experienced a severe drug eruption, including purpura and hypofibrinogenemia, from allopurinol treatment for gout. This rare adverse reaction highlights the need for vigilance in gout medication management.
Area of Science:
- Dermatology
- Pharmacology
- Hematology
Background:
- Allopurinol is a common medication for managing hyperuricemia and gout.
- Drug eruptions are known adverse reactions to various medications, including allopurinol.
- Purpura and hypofibrinogenemia are serious conditions affecting blood clotting and skin integrity.
Observation:
- An 80-year-old male presented with widespread erythema, maculopapular rash with itching, and purpuric lesions after initiating oral allopurinol for gout.
- The patient's purpuric rash expanded during hospitalization, accompanied by the development of hypofibrinogenemia.
Findings:
- This case represents the first reported instance of allopurinol-induced purpura and hypofibrinogenemia.
- Successful treatment involved intravenous fibrinogen, cryoprecipitate, and high-dose methylprednisolone, leading to the resolution of the skin rash.
Implications:
- This case underscores a rare but severe potential adverse effect of allopurinol, necessitating careful patient monitoring.
- The underlying pathophysiology of allopurinol-induced purpura and hypofibrinogenemia requires further investigation.
- Clinicians should consider this reaction in patients presenting with purpuric eruptions while on allopurinol therapy.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:24Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
01:29Venous Thrombosis III: Interprofessional Care
481
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481
01:16Drug toxicity: Idiosyncratic Reactions
219
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
219
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:25Jaundice
26
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
26